Thursday, August 20, 2026

Moderna reports positive Phase 3 melanoma data

Moderna has reported positive topline results from the Phase 3 INTerpath-001 trial. The study evaluated intismeran autogene, an investigational individualized neoantigen therapy based on mRNA, in combination with pembrolizumab as adjuvant treatment for patients with completely resected Stage IIB to IV melanoma.

The company said the study was conducted with Merck. Moderna framed the outcome as an important step for a treatment concept that uses information from an individual tumor to design a patient-specific cancer therapy.

Comparison with standard treatment

The combination was tested against pembrolizumab alone, which is a current standard-of-care option in this setting. According to Moderna, the regimen is the first and only combination to show a clinically meaningful improvement over pembrolizumab alone.

The company post did not provide detailed efficacy figures or safety data. Moderna said it will continue to follow patients in the study and assess additional secondary endpoints, including overall survival.

Development program continues

Moderna and Merck are continuing to study intismeran autogene with pembrolizumab and with other anti-cancer therapies. The candidate is also being evaluated as monotherapy. Moderna said the broader program spans multiple tumor types and disease stages, including melanoma, lung, bladder and kidney cancers.

For the pharmaceutical and biotech sector, the announcement is notable because it points to the clinical maturation of individualized mRNA-based cancer therapies. Regulatory review remains a key next step. Moderna said it plans to engage with regulators about potential submissions.

mRNA platform moves further into oncology

Moderna noted that its mRNA platform has already led to five approved products, mainly in infectious diseases. The latest results bring oncology applications of the platform further into focus.

The announcement also contains several forward-looking statements. Whether and when intismeran autogene in combination with pembrolizumab could become available to patients outside clinical trials remains open.